The Japanese Ministry of Health, Labor and Welfare gave Novo Nordisk (NYSE:NVO) the green light to market its once-weekly type II diabetes drug, Ozempic, Reuters reported today.
The pharma company’s drug, semaglutide, is a glucagon-like peptide-1 analog that mimics an intestinal hormone to trigger insulin production in people with diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post Japan approves Novo Nordisk’s once-weekly Type II diabetes drug appeared first on MassDevice.
from MassDevice http://ift.tt/2IOyrFG
Cap comentari:
Publica un comentari a l'entrada